Literature DB >> 34077524

Redefining therapeutic success in HIV patients: an expert view.

Antonio Antela1, Antonio Rivero2,3, Josep M Llibre4, Santiago Moreno5.   

Abstract

Thanks to advances in the field over the years, HIV/AIDS has now become a manageable chronic condition. Nevertheless, a new set of HIV-associated complications has emerged, related in part to the accelerated ageing observed in people living with HIV/AIDS, the cumulative toxicities from exposure to antiretroviral drugs over decades and emerging comorbidities. As a result, HIV/AIDS can still have a negative impact on patients' quality of life (QoL). In this scenario, it is reasonable to believe that the concept of therapeutic success, traditionally associated with CD4 cell count restoration and HIV RNA plasma viral load suppression and the absence of drug resistances, needs to be redefined to include other factors that reach beyond antiretroviral efficacy. With this in mind, a group of experts initiated and coordinated the RET Project, and this group, using the available evidence and their clinical experience in the field, has proposed new criteria to redefine treatment success in HIV, arranged into five main concepts: rapid initiation, efficacy, simplicity, safety, and QoL. An extensive review of the literature was performed for each category, and results were discussed by a total of 32 clinicians with experience in HIV/AIDS (4 coordinators + 28 additional experts). This article summarizes the conclusions of these experts and presents the most updated overview on the five topics, along with a discussion of the experts' main concerns, conclusions and/or recommendations on the most controversial issues.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Entities:  

Year:  2021        PMID: 34077524     DOI: 10.1093/jac/dkab168

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients.

Authors:  Mehran Monchi; Thomas Bruneau; Sebastien Jochmans; David Veyer; Aurelia Pitsch; Olivier Ellrodt; Marie Picque; Valérie Taly; Oumar Sy; Sandie Mazerand; Sylvain Diamantis; Hélène Péré
Journal:  iScience       Date:  2022-03-14

2.  Reversibility of Central Nervous System Adverse Events in Course of Art.

Authors:  Lucia Taramasso; Giancarlo Orofino; Elena Ricci; Barbara Menzaghi; Giuseppe Vittorio De Socio; Nicola Squillace; Giordano Madeddu; Francesca Vichi; Benedetto Maurizio Celesia; Chiara Molteni; Federico Conti; Filippo Del Puente; Eleonora Sarchi; Goffredo Angioni; Antonio Cascio; Carmela Grosso; Giustino Parruti; Antonio Di Biagio; Paolo Bonfanti
Journal:  Viruses       Date:  2022-05-11       Impact factor: 5.818

3.  Breaking the fourth wall: Integrating quality into HIV care.

Authors:  Sasheela Sri La Sri Ponnampalavanar; Ian John Woolley
Journal:  Indian J Med Res       Date:  2021-06       Impact factor: 5.274

4.  DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

Authors:  Carmen Hidalgo-Tenorio; Juan Pasquau; David Vinuesa; Sergio Ferra; Alberto Terrón; Isabel SanJoaquín; Antoni Payeras; Onofre Juan Martínez; Miguel Ángel López-Ruz; Mohamed Omar; Javier de la Torre-Lima; Ana López-Lirola; Jesús Palomares; José Ramón Blanco; Marta Montero; Coral García-Vallecillos
Journal:  Viruses       Date:  2022-03-04       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.